La imperiosa necesidad de reconstruir el sistema valorativo de los aportes científicos
DOI:
https://doi.org/10.17533/udea.rfnsp.e344778Downloads
Referências
Ioannidis JP. Why most published research findings are false. PLOS Medicine. 2005;2(8):0696-0701. DOI: https://doi.org/10.1371/journal.pmed.0020124
Begley CG, Ioannidis JP. Reproducibility in science: Improving the standard for basic and preclinical research. Circulation Research.2015;116(1):116-26. DOI: https://doi.org/10.1161/CIRCRESAHA.114.303819
Baker M. 1,500 scientists lift the lid on reproducibility. Nature. 2016;533:452-4.
Silva LC. Crisis en la calidad de la ciencia médica: el papel del arbitraje en el nuevo desorden editorial. iris. Informação, Memória e Tecnologia.2018;4(1):8-21.
Gøtzsche P. Deadly medicines and organized crime. How big pharma has corrupted healthcare. New York: Radcliffe, 2013.
Budapest Open Access Initiative. Ten years on from the Budapest Open Access Initiative: Setting the default to open. Budapest Open Access Initiative; 2012. Disponible en: http://www.budapestopenaccessinitiative.org/boai-10-recommendations
Nosek BA, Bar-Anan Y. Scientific communication is changing and scientists should lead the way. Psychological Inquiry. 2012;23(3):308-14.
Bosman, J. Nine reasons why impact factors fail and using them may harm science. I&M / I&O 2.0; 2013. Disponible en: https://im2punt0.wordpress.com/2013/11/03/nine-reasons-why-impact-factors-fail-and-using-them-may-harm-science/
Parra S. Auge, caída y auge del remdesivir, el “esperanzador” antiviral para combatir el COVID-19; 2020. Disponible en: https://www.xataka.com/medicina-y-salud/auge-caida-auge-remdesivir-esperanzador-antiviral-para-combatir-covid-19
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of covid-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents; 2020:56(1): 105949. doi:https://doi.org/10.1016/j.ijantimicag.2020.105949
Baker P, Rogers K, et al. Trump’s aggressive advocacy of malaria drug for treating coronavirus divides medical community. The New York Times. 2020 abr. 6.
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Retracted: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of covid-19: A multinational registry analysis. The Lancet, 2020(mayo 22):1-10. DOI: https://doi.org/10.1016/S0140-6736(20)31180-6
WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 –interim who solidarity trial results. 2020; oct. 15. Disponible en: https://bit.ly/3nYAPhC
Publicado
Como Citar
Edição
Seção
Licença
El autor o los autores conserva(n) los derechos morales y cede(n) los derechos patrimoniales que corresponderán a la Universidad de Antioquia, para publicarlo, distribuir copias electrónicas, incluirlas en servicios de indización, directorios o bases de datos nacionales e internacionales en Acceso Abierto, bajo la licencia Creative Commons Atribución-No Comercial-Compartir Igual 4.0 Internacional Comercial (CC BY-NC-SA) la cual permite a otros distribuir, remezclar, retocar y crear a partir de la obra de modo no comercial, siempre y cuando se dé crédito respectivo y licencien las nuevas creaciones bajo las mismas condiciones.